·PIB·15 marks·250–350 words

How does the RDI Scheme's use of debt and convertible instruments, rather than grants, address the commercialisation gap in Indian deep-tech?

New · District CollectorCan you hold the district for 72 hours?Floods, a heatwave, an outbreak, a grievance queue. Take the decisions, see the consequences.Play →
In this answer
  1. The commercialisation gap
  2. How debt and convertible instruments bridge it
  3. Limitations

Indian deep-tech firms often stall in the "valley of death". This is the costly stage between a tested prototype and a commercial product, where grants run out and private capital stays away. The RDI Scheme (₹1 lakh crore over six years; nodal department: DST) [2] targets this gap with long-tenor loans and equity instead of grants.

The commercialisation gap

  • Grants usually fund lab research. Scale-up needs pilot plants, certification and first customers, which take larger and more patient capital.
  • Venture capital avoids long gestation and technology risk. Banks ask for collateral that early-stage firms lack.

How debt and convertible instruments bridge it

  • Low-cost, patient capital: support is mainly long-tenor, low- or nil-interest financing, expected to be largely unsecured [2]. This removes the collateral barrier.
  • Stage-specific targeting: the TDB–NeoSeeker Metals deal finances an urban-mining technology from TRL-5 to TRL-9, i.e. commercial scale [1].
  • Optionally Convertible Debt (OCD): the loan can convert into equity [1]. The firm gets relief if repayment strains it, and the state gets a share of the gains if the firm succeeds.
  • Crowding-in: ₹10 crore of the ₹20 crore project comes from the RDI Fund and the rest from the firm [1]. The corpus reaches firms through second-level fund managers such as TDB [2][3].
  • Revolving corpus, market discipline: grants and short-term loans are excluded [3]. Repayments refill the fund, and firms must show a viable business case.
Lab grants (TRL 1–4) → [Valley of death: TRL 5–8] → Market (TRL 9)
                              ↑
              RDI: low-interest loan / OCD / equity

Fig: Where RDI financing sits

Limitations

  • Debt vs technology risk: the loan must be repaid even if the technology fails. A young firm services debt before it has steady revenue.
  • Opaque conversion: the release does not say who decides on conversion or on what terms [1]. Unsecured lending raises the stakes for public money.
  • Market-side risks: viable technology still needs inputs and buyers. For example, formal battery recyclers struggle against informal collection channels [4].

By replacing one-time grants with repayable, convertible finance, the RDI Scheme turns public R&D money into patient risk capital for the valley of death. Several steps would sharpen it: tranche-wise disbursal linked to TRL milestones, transparent conversion rules, and published project outcomes. Together they would advance Atmanirbhar Bharat and SDG 9 (Industry, Innovation and Infrastructure).

Sources

  1. 1PIB – TDB-DST Signs Agreement with NeoSeeker Metals under RDI Fund to Advance Indigenous Critical Minerals Recovery Technology (16 Nov 2026)OCD instrument, ₹20 crore cost / ₹10 crore RDI share, TRL-5→9; conversion terms not disclosed
  2. 2PIB – Cabinet Approves Research Development and Innovation (RDI) Scheme₹1 lakh crore corpus, DST nodal, long-tenor low/nil-interest unsecured financing, two-tier structure
  3. 3PIB – Parliament Question: Operationalisation of Deep Tech Fund of FundsTDB as second-level fund manager; grants and short-term loans not provided
  4. 4NITI Aayog – Advanced Chemistry Cell Battery Reuse and Recycling Market in India (2022)informal channels dominate battery collection

More from this note